Taken together, our findings highlight that the aberrant accumulation of ARID1B, which could be due to lower promoter methylation, significantly correlates with a poor prognosis in breast cancer patients.[25, 26] Our findings suggest that elevated ARID1B levels in TNBC not only drive tumor growth through enhanced cell proliferation but also promote stem cell‐like characteristics associated with cancer progression and therapy resistance. This evidence concerns the gene ARID1B and breast carcinoma.